Dr. Dan Lazar received his Ph.D. in biological chemistry from the University of Michigan and then completed a postdoctoral fellowship focused on cell signaling at Warner Lambert/Parke-Davis. Subsequently, he was a Team Leader and Senior Scientist at Eli Lilly within the metabolic disease drug-discovery area for well over a decade where he gained extensive experience in the development, validation and implementation of cell-based and biochemical assays for drug discovery. As a Group Leader and Senior Research Scientist at Promega, Dan and his colleagues are principally focused on delivering novel cell-based assays for the quantitative assessment of various aspects of cell health to assist academic and industrial investigators.
Dr. Gary Allenby has a Ph.D. in reproductive toxicology, and studied the pharmacology of retinoid biology as a post-doc at Hoffmann La Roche, USA. He returned to the UK in 1995 to join the Lead Generation group at Glaxo Wellcome. There he developed cell-based assays for high throughput screening and worked with vendors to validate new technologies for screening and automated HTS. In 2000, he joined the Hit Identification group at AstraZeneca, developing assays for respiratory and inflammatory disease while continuing to work with vendors and automated assays.
In 2011, Dr. Allenby became a founding entrepreneur of Aurelia Bioscience, a pre-clinical contract research organization located in Nottingham, UK. Aurelia Bioscience focuses on developing and implementing innovative cell-based assays for screening, and collaborate with vendors to deliver value-adding data for drug discovery purposes.